Shots:
- Astellas has entered into definitive agreement with YASKAWA to establish a joint venture for the development of a cell therapy product manufacturing platform based on previously signed MoU (May 21, 2024)
- In joint venture, Astellas will own 60% & YASKAWA 40% with $30.14M (¥4.5B) capital & expected to establish in Sept 2025, subject to pending regulatory approvals & closing conditions
- Joint entity will leverage Astellas’ R&D & manufacturing expertise with YASKAWA’s dual-arm robot Maholo to optimize precision manufacturing, enable one-click GMP-compliant process transfer, & develop cell therapies for partners while fostering collaboration with startups & academic institutions
Ref: Astellas | Image: Astellas & YASKAWA
Related News:- Japan’s MHLW Receives NDA for Conditional Approval of Astellas’ Avacincaptad Pegol to Treat Geographic Atrophy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
